The production of the Pfizer-BioNTech COVID-19 vaccine was an unprecedented undertaking, characterized by its speed, scale, and global complexity. Unlike traditional vaccine manufacturing, which typically spans several years to optimize for efficiency and cost, the urgency of the pandemic necessitated immediate production using the initial laboratory-formulated process. This rapid scale-up involved a sophisticated three-stage manufacturing process,
relying on a vast network of suppliers and facilities across multiple continents, highlighting the intricate global collaboration required to combat the health crisis.
The Three-Stage Production Process
The manufacturing of the Pfizer-BioNTech vaccine is divided into three distinct stages, each with specific locations and critical steps. The first stage involves the molecular cloning of DNA plasmids that code for the spike protein. This is achieved by infusing these plasmids into Escherichia coli bacteria. For all global markets, this initial stage is conducted at a small Pfizer pilot plant located in Chesterfield, Missouri, in the United States. After approximately four days of bacterial growth, the bacteria are processed to recover and purify the desired DNA product, a process that takes about a week and a half. The purified DNA is then bottled, frozen, and transported, sometimes even using Pfizer's company jet and helicopter due to the critical need for safe and swift delivery.
The second stage of production focuses on creating the messenger RNA (mRNA) strands. This takes place at a Pfizer plant in Andover, Massachusetts, in the United States, and at BioNTech's facilities in Germany. The DNA from the first stage serves as a template to build the mRNA strands, a process that typically takes about four days. Once the mRNA is synthesized and purified, it is frozen in large plastic bags, each capable of holding up to 10 million doses, and then transported to the next manufacturing site.
Final Assembly, Quality Control, and Global Distribution
The third and final stage of manufacturing occurs at Pfizer plants in Portage, Michigan, in the United States, and Puurs, Belgium. Here, the mRNA is combined with lipid nanoparticles, which act as carriers to deliver the mRNA into human cells and also function as adjuvants. A key component, the PEGylated lipid ALC-0159, is provided by Croda International subsidiary Avanti Polar Lipids. As of November 2020, the major bottleneck in the manufacturing process was this step of combining mRNA with lipid nanoparticles. After this, the vaccine is filled into vials, boxed, and frozen. This stage, from mRNA and lipids to finished vials, takes only four days, but each lot then undergoes several weeks of deep-freeze storage and rigorous verification against 40 quality-control measures.
Pfizer revealed in February 2021 that the entire production sequence initially took about 110 days on average, with efforts underway to reduce this to 60 days. More than half of this time is dedicated to extensive testing and quality assurance at each stage. The process relies on 280 components sourced from 25 suppliers in 19 countries, underscoring its global supply chain. Before May 2021, the Pfizer plant in Puurs was responsible for all vials destined outside the United States, meaning doses for the Americas (excluding the U.S.) required at least two transatlantic flights. BioNTech also expanded its production capacity by acquiring a manufacturing facility in Marburg, Germany, which, once fully operational, was projected to produce up to 750 million doses per year, further bolstering the global supply.
